Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INGN 
Inogen Inc (INGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.28% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 186.87M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 379939 | Beta 1.16 | 52 Weeks Range 6.14 - 13.33 | Updated Date 04/1/2025 |
52 Weeks Range 6.14 - 13.33 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.69% | Operating Margin (TTM) -12.76% |
Management Effectiveness
Return on Assets (TTM) -7.78% | Return on Equity (TTM) -18.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 92477331 | Price to Sales(TTM) 0.56 |
Enterprise Value 92477331 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -17.6 | Shares Outstanding 26887200 | Shares Floating 21531909 |
Shares Outstanding 26887200 | Shares Floating 21531909 | ||
Percent Insiders 11.46 | Percent Institutions 79.63 |
Analyst Ratings
Rating 3.25 | Target Price 10 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inogen Inc
Company Overview
History and Background
Inogen Inc. was founded in 2001. It develops, manufactures, and markets portable oxygen concentrators (POCs) used by patients with chronic respiratory conditions. The company has focused on improving patient independence and quality of life through its innovative products.
Core Business Areas
- Respiratory Therapy: Development, manufacturing, and sale of portable oxygen concentrators for individuals requiring supplemental oxygen therapy.
- Direct-to-Consumer Sales: Direct sales of POCs to patients through Inogen's website and sales representatives.
- Business-to-Business Sales: Sales of POCs to home healthcare providers, durable medical equipment suppliers, and other distributors.
Leadership and Structure
The leadership team typically includes a CEO, CFO, CTO, and other executive officers. The organizational structure is generally hierarchical, with departments focused on research and development, manufacturing, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Inogen One G5: A portable oxygen concentrator designed for active lifestyles, offering up to 13 hours of battery life. Inogen products account for about 25% of the portable oxygen concentrator market. Competitors include ResMed, Philips Respironics, and CAIRE Inc. The revenue for the G5 is not publicly disaggregated.
- Inogen One G4: A smaller, lighter portable oxygen concentrator for on-the-go use. Inogen products account for about 25% of the portable oxygen concentrator market. Competitors include ResMed, Philips Respironics, and CAIRE Inc. The revenue for the G4 is not publicly disaggregated.
- Inogen At Home: A stationary oxygen concentrator designed for home use. Inogen products account for about 25% of the portable oxygen concentrator market. Competitors include ResMed, Philips Respironics, and CAIRE Inc. The revenue for the Inogen at home is not publicly disaggregated.
Market Dynamics
Industry Overview
The respiratory therapy market is driven by the aging population, increasing prevalence of respiratory diseases (COPD, asthma), and advancements in oxygen therapy technology. The market is competitive, with several large players and smaller specialized companies.
Positioning
Inogen positions itself as a leader in portable oxygen concentrators, focusing on innovation, portability, and patient-centric design. Its competitive advantages include its patented technology, direct-to-consumer sales model, and brand reputation.
Total Addressable Market (TAM)
The global respiratory care devices market is projected to reach over $30 billion by 2030. Inogen is positioned to capture a significant share through its focus on portable oxygen concentrators within this broader market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Innovative technology
- Direct-to-consumer sales model
- Portable and lightweight products
- Strong intellectual property portfolio
Weaknesses
- High product price
- Reliance on direct sales model
- Limited product diversification
- Fluctuations in reimbursement rates
Opportunities
- Expanding international presence
- Developing new products for respiratory care
- Acquiring complementary businesses
- Increasing awareness of COPD and respiratory diseases
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturn
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- RMD
- PHG
- CAIRE Inc. (Privately Held)
Competitive Landscape
Inogen's competitive advantages include its focus on portable oxygen concentrators, direct-to-consumer sales, and innovative technology. Disadvantages include its higher product price and reliance on a single product category. ResMed and Philips are larger, more diversified companies with greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Inogen has experienced growth in the past driven by increasing adoption of POCs and its direct-to-consumer sales strategy.
Future Projections: Analyst projections vary, but generally forecast continued growth in revenue, driven by the expanding respiratory care market and new product launches. These projections are subject to changes in market conditions and competitive pressures.
Recent Initiatives: Recent initiatives may include expanding its product line, increasing marketing efforts, and pursuing strategic partnerships or acquisitions.
Summary
Inogen is a key player in the portable oxygen concentrator market, known for its innovative and lightweight products. Its direct-to-consumer sales model gives it an advantage, but it also faces competition from larger companies. The company needs to diversify its product line and carefully navigate healthcare regulations to maintain its growth trajectory. Financial data and metrics were not able to be fully retrieved at this time.
Similar Companies
DVAX
Dynavax Technologies Corporation
DVAX
Dynavax Technologies Corporation
PHG
Koninklijke Philips NV ADR
PHG
Koninklijke Philips NV ADR
RMD
ResMed Inc
RMD
ResMed Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Industry Analysis
- Financial News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary depending on the source. Financial performance data is not updated in real time and may not reflect current performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inogen Inc
Exchange NASDAQ | Headquaters Goleta, CA, United States | ||
IPO Launch date 2014-02-14 | President, CEO & Director Mr. Kevin R. M. Smith | ||
Sector Healthcare | Industry Medical Devices | Full time employees 766 | Website https://provider.inogen.com/en |
Full time employees 766 | Website https://provider.inogen.com/en | ||
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.